Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 4/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27829250 | 0.89 | SLC6A2 (0.54) | HIF1ASMN1; SMN2SLC6A2TAAR1CYP3A4 | |
| SCHEMBL29290738 | 0.84 | SMN1; SMN2 (0.48) | HIF1ASMN1; SMN2SLC6A2TAAR1CYP3A4 | |
| SCHEMBL27566087 | 0.82 | HIF1A (0.41) | HIF1ASMN1; SMN2SLC6A2TAAR1CYP3A4 | |
| SCHEMBL28487224 | 0.81 | SMN1; SMN2 (0.46) | HIF1ASMN1; SMN2SLC6A2TAAR1CYP3A4 | |
| SCHEMBL19329198 | 0.79 | SMN1; SMN2 (0.44) | HIF1ASMN1; SMN2SLC6A2TAAR1CYP3A4 | |
| SCHEMBL8759 | 0.79 | SLC6A2 (0.56) | HIF1ASMN1; SMN2SLC6A2TAAR1CYP3A4 | |
| Hydrochloric Acid SCHEMBL3136989 | 0.77 | SLC6A2 (0.54) | HIF1ASMN1; SMN2SLC6A2TAAR1CYP3A4 | |
| SCHEMBL7418992 | 0.77 | MMP8 (0.47) | HIF1ASMN1; SMN2SLC6A2TAAR1MAPT | |
| SCHEMBL27908890 | 0.77 | SMN1; SMN2 (0.57) | HIF1ASMN1; SMN2SLC6A2TAAR1CYP3A4 | |
| SCHEMBL5268840 | 0.76 | SLC6A2 (0.57) | HIF1ASMN1; SMN2SLC6A2TAAR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | claimed |
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | GLP1R, GIPR, IAPP | HIF1A 2995/4885SMN1; SMN2 1582/4885SLC6A2 3676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.